Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 221-231

  Bossi, Daniela ^a   Carlomagno, Francesca ^b   Pallavicini, Isabella ^a   Pruneri, Giancarlo ^a   Trubia, Maurizio ^a   Raviele, Paola Rafaniello ^a   Marinelli, Alessandra ^c   Anaganti, Suresh ^b   Cox, Maria Christina ^d   Viale, Giuseppe ^a   Santoro, Massimo ^b   Di Fiore, Pier Paolo ^a,c,e   Minucci, Saverio ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Chromosomal translocation; FGFR1OP RET; Leukemia; Mast cells; Murine models; Myeloproliferative disorders

Indexed keywords

CYTOKINE RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1 OP REARRANGED DURING TRANSFECTION PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; STAT PROTEIN; UNCLASSIFIED DRUG; PROTEIN RET;

ACUTE GRANULOCYTIC LEUKEMIA; ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BONE MARROW CELL; BONE MARROW DEPRESSION; CARBOXY TERMINAL SEQUENCE; CELL PERMEABILIZATION; CELL STRAIN 3T3; CELL STRAIN HEK293; CELL SURVIVAL; CHROMOSOME 10; CHROMOSOME 6; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY FORMING CELL; COLONY FORMING UNIT; CONTROLLED STUDY; EXON; EXPRESSION VECTOR; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; MAST CELL; METAPHASE; MOLECULAR CLONING; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; GENE FUNCTION; HEMATOLOGIC MALIGNANCY; MAST CELL LEUKEMIA; MOUSE; NONHUMAN;

MURINAE; MUS;

CHROMOSOMAL TRANSLOCATION; FGFR1OP-RET; LEUKEMIA; MAST CELLS; MURINE MODELS; MYELOPROLIFERATIVE DISORDERS;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 6; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; TRANSLOCATION, GENETIC;

EID: 84894337153     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.11.004     Document Type: Article

References (49)

1. Baker S.J., Rane S.G., Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 2007, 26:6724-6737.
2. Ballerini P., Struski S., Cresson C., Prade N., Toujani S., Deswarte C., Dobbelstein S., Petit A., Lapillonne H., Gautier E.F., Demur C., Lippert E., Pages P., Mansat-De Mas V., Donadieu J., Huguet F., Dastugue N., Broccardo C., Perot C., Delabesse E. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia 2012, 26:2384-2389.
3. Cheng L., Fu J., Tsukamoto A., Hawley R.G. Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells. Nat. Biotechnol. 1996, 14:606-609.
4. Cox M.C., Panetta P., Venditti A., Abruzzese E., Del Poeta G., Cantonetti M., Amadori S. New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. Leuk. Res. 2001, 25:349-351.
5. Dexter T.M., Allen T.D., Lajtha L.G. Conditions controlling the proliferation of haemopoietic stem cells invitro. J.Cell. Physiol. 1997, 91:335-344.
6. Endicott J.A., Noble M.E.M., Johnson L.N. The structural basis for control of eukaryotic protein kinases. Annu. Rev. Biochem. 2012, 81:587-613.
7. Gelsi-Boyer V., Trouplin V., Roquain J., Adélaïde J., Carbuccia N., Esterni B., Finetti P., Murati A., Arnoulet C., Zerazhi H., Fezoui H., Tadrist Z., Nezri M., Chaffanet M., Mozziconacci M.J., Vey N., Birnbaum D. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br. J. Haematol. 2010, 151:365-375.
8. Hehlmann R., Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica 2008, 93:1765-1769.
9. Insinga A., Monestiroli S., Ronzoni S., Carbone R., Pearson M., Pruneri G., Viale G., Appella E., Pelicci P., Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 2004, 23:1144-1154.
10. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
11. Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y., Traina F., Visconte V., Sugimoto Y., Prince C., O'Keefe C., Hsi E.D., List A., Sekeres M.A., Rao A., McDevitt M.A., Maciejewski J.P. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011, 118:3932-3941.
12. Kohno T., Ichikawa H., Totoki Y., Yasuda K., Hiramoto M., Nammo T., Sakamoto H., Tsuta K., Furuta K., Shimada Y., Iwakawa R., Ogiwara H., Oike T., Enari M., Schetter A.J., Okayama H., Haugen A., Skaug V., Chiku S., Yamanaka I., Arai Y., Watanabe S., Sekine I., Ogawa S., Harris C.C., Tsuda H., Yoshida T., Yokota J., Shibata T. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 2012, 18:375-377.
13. Koopmans S.M., Van Marion A.M., Schouten H.C. Myeloproliferative neoplasia: a review of clinical criteria and treatment. Neth. J. Med. 2012, 70:159-166.
14. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N.Engl. J. Med. 2005, 352:1779-1790.
15. Kundranda M.N., Tibes R., Mesa R.A. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?. Curr. Hematol. Malig Rep. 2012, 7:78-86.
16. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., Stevens-Linders E., van Hoogen P., van Kessel A.G., Raymakers R.A., Kamping E.J., Verhoef G.E., Verburgh E., Hagemeijer A., Vandenberghe P., de Witte T., van der Reijden B.A., Jansen J.H. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41:838-842.
17. Lelièvre H., Chevrier V., Tassin A.M., Birnbaum D. Myeloproliferative disorder FGFR1OP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome. Mol. Cancer 2008, 7:1-11.
18. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 25:1117-1134.
19. Li J., Spensberger D., Ahn J.S., Anand S., Beer P.A., Ghevaert C., Chen E., Forrai A., Scott L.M., Ferreira R., Campbell P.J., Watson S.P., Liu P., Erber W.N., Huntly B.J., Ottersbach K., Green A.R. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, 116:1528-1538.
20. Li J., Kent D.G., Chen E., Green A.R. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis. Models Mech. 2011, 4:311-317.
21. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., Curran J.A., Balasubramanian S., Bloom T., Brennan K.W., Donahue A., Downing S.R., Frampton G.M., Garcia L., Juhn F., Mitchell K.C., White E., White J., Zwirko Z., Peretz T., Nechushtan H., Soussan-Gutman L., Kim J., Sasaki H., Kim H.R., Park S.I., Ercan D., Sheehan C.E., Ross J.S., Cronin M.T., Jänne P.A., Stephens P.J. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 2012, 18:382-384.
22. Matsumura I., Mizuki M., Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci. 2008, 99:479-485.
23. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., Navolanic P.M., Terrian D.M., Franklin R.A., D'Assoro A.B., Salisbury J.L., Mazzarino M.C., Stivala F., Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006, 46:249-279.
24. Mikolajka A., Yan X., Popowicz G.M., Smialowski P., Nigg E.A., Holak T.A. Structure of the N-terminal domain of the FGFR1OP (FGFR1OP) protein and implications for its dimerization and centrosomal localization. J.Mol. Biol. 2006, 359:863-875.
25. Minucci S., Monestiroli S., Giavara S., Ronzoni S., Marchesi F., Insinga A., Diverio D., Gasparini P., Capillo M., Colombo E., Matteucci C., Contegno F., Lo-Coco F., Scanziani E., Gobbi A., Pelicci P.G. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002, 100:2989-2995.
26. Nikoloski G., van der Reijden B.A., Jansen J.H. Mutations in epigenetic regulators in myelodysplastic syndromes. Int. J. Hematol. 2012, 1:8-16.
27. Pardanani A. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am. J. Hematol. 2012, 87:401-411.
28. Pittoni P., Piconese S., Tripodo C., Colombo M.P. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 2011, 30:757-769.
29. Plaza Menacho I., Koster R., van der Sloot A.M., Quax W.J., Osinga J., van der Sluis T., Hollema H., Burzynski G.M., Gimm O., Buys C.H., Eggen B.J., Hofstra R.M. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res. 2005, 65:1729-1737.
30. Plaza-Menacho I., van der Sluis T., Hollema H., Gimm O., Buys C.H., Magee A.I., Isacke C.M., Hofstra R.M., Eggen B.J. Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J.Biol. Chem. 2007, 282:6415-6424.
31. Popovici C., Zhang B., Grégoire M.J., Jonveaux P., Lafage-Pochitaloff M., Birnbaum D., Pébusque M.J. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FGFR1OP, to fibroblast growth factor receptor 1. Blood 1999, 93:1381-1389.
32. Santoro M., Dathan N.A., Berlingieri M.T., Bongarzone I., Paulin C., Grieco M., Pierotti M.A., Vecchio G., Fusco A. Molecular characterization of NCOA4-RET; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994, 9:509-516.
33. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M., Fusco A., Vecchio G., Matoskova B., Kraus M.H., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995, 267:381-383.
34. Santoro M., Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2:42-52.
35. Sloma I., Jiang X., Eaves A.C., Eaves C.J. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010, 24:1823-1833.
36. Smithgall T.E., Briggs S.D., Schreiner S., Lerner E.C., Cheng H., Wilson M.B. Control of myeloid differentiation and survival by Stats. Oncogene 2000, 19:2612-2618.
37. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
38. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001, 12:361-373.
39. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., Asaka R., Hamanaka W., Ninomiya H., Uehara H., Lim Choi Y., Satoh Y., Okumura S., Nakagawa K., Mano H., Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 2012, 18:378-381.
40. Tefferi A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., Patnaik M.M., Hanson C.A., Pardanani A., Gilliland D.G., Levine R.L. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345.
41. Tefferi A. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Leuk. Res. 2012, 36:1481-1489.
42. Thol F., Friesen I., Damm F., Yun H., Weissinger E.M., Krauter J., Wagner K., Chaturvedi A., Sharma A., Wichmann M., Göhring G., Schumann C., Bug G., Ottmann O., Hofmann W.K., Schlegelberger B., Heuser M., Ganser A. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J.Clin. Oncol. 2011, 29:2499-2506.
43. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., Marone G., Nuñez R., Akin C., Sotlar K., Sperr W.R., Wolff K., Brunning R.D., Parwaresch R.M., Austen K.F., Lennert K., Metcalfe D.D., Vardiman J.W., Bennett J.M. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 2001, 25:603-625.
44. Vardiman J. The classification of MDS: from FAB to WHO and beyond. Leuk. Res. 2012, 36:1453-1458.
45. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellström-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2008, 114:937-951.
46. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., Fulton R., Schmidt H., Kalicki-Veizer J., O'Laughlin M., Kandoth C., Baty J., Westervelt P., DiPersio J.F., Mardis E.R., Wilson R.K., Ley T.J., Graubert T.A. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
47. Walz C., Ahmed W., Lazarides K., Betancur M., Patel N., Hennighausen L., Zaleskas V.M., Van Etten R.A. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice. Blood 2012, 119:3550-3560.
48. Yamazaki J., Taby R., Vasanthakumar A., Macrae T., Ostler K.R., Shen L., Kantarjian H.M., Estecio M.R., Jelinek J., Godley L.A., Issa J.P. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012, 7:201-207.
49. Yan X., Habedanck R., Nigg E.A. A complex of two centrosomal proteins, CAP350 and FGFR1OP, cooperates with EB1 in microtubule anchoring. Mol. Biol. Cell 2006, 17:634-644.